Description

Buy Virgan Ganciclovir 1.5 mg/g 5g eye gel

Description of  Virgan 1.5 mg/g eye gel:

1 g gel contains 1.5 mg ganciclovir (0.15% w/w).
Excipient with known effect: benzalkonium chloride (75 µg/g), carbomer, sorbitol (E 420), sodium hydroxide, purified water.

Therapeutic Indications of  Virgan 1.5 mg/g eye gel:

Virgan Ganciclovir  treatment of acute herpetic keratitis (dendritic and geographic ulcers).

Contraindications for use Virgan 1.5 mg/g eye gel:

Hypersensitivity to ganciclovir or acyclovir.

Special Warnings and Precautions for USE of  Virgan 1.5 mg/g eye gel:

This medicinal product is not indicated in the treatment of cytomegalovirus (CMV) retina infections.
Efficacy in other viral types of keratoconjunctivitis has not been demonstrated.
No specific clinical studies were performed in immunodepressed subjects.
This medicine contains 0.375 mg benzalkonium chloride in each tube of 5 g.
Benzalkonium chloride may also cause eye irritation, especially in dry eyes or disorders of the cornea. Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. Remove contact lenses prior to application and wait at least 15 min before reinsertion.
Benzalkonium chloride may also cause eye irritation, especially in dry eyes or disorders of the cornea. Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. Remove contact lenses prior to application and wait at least 15 min before reinsertion.

Interaction with Other Medicinal Products:

If more than one topical ophthalmic drug is being used, the drugs should be administered at least fifteen minutes apart. VIRGAN should be instilled last.
Although the quantities of ganciclovir passing into the general circulation after ophthalmic use are small, the risk of drug interactions cannot be ruled out. Interactions with ganciclovir administered systemically have been observed:
Binding of ganciclovir to plasma proteins is only about 1-2% and drug interactions involving binding site displacement are not anticipated.
It is possible that drugs which inhibit replication of rapidly dividing cell populations such as bone marrow, spermatogonia and germinal layers of skin and gastrointestinal mucosa might have combined additive toxic effects when used concomitantly with, before or after ganciclovir. Because of the possibility of additive toxicity with co-administration of drugs such as dapsone, pentamidine, flucystosine, vincristine, vinblastine, adriamycin, amphotericin B, trimethoprim/sulpha combinations or other nucleoside analogues, combination with ganciclovir therapy should be used only if the potential benefits outweigh the risks.
Since both zidovudine and ganciclovir can result in neutropenia, it is recommended that these two drugs should not be given concomitantly during induction treatment with ganciclovir. Maintenance ganciclovir treatment plus zidovudine at the recommended dose resulted in severe neutropenia in most patients studied to date.
Generalised seizures have been reported in patients taking ganciclovir and imipenem-cilastatin concomitantly.
It is also possible that probenecid, as well as other drugs which inhibit renal tubular secretion or resorption, may reduce renal clearance of ganciclovir and could increase the plasma half-life of ganciclovir.

Use in Fertility, Pregnancy & Lactation:

There is insufficient experience regarding administration during pregnancy or lactation for evaluating the safety of VIRGAN during these periods.
Teratogenicity and effect on fertility have been observed in animal studies with orally or intravenous administered ganciclovir. Furthermore ganciclovir had shown potential genotoxicity with low safety margin.
Consequently, administration during pregnancy or lactation is therefore not recommended, except in the absence of an alternative treatment. For women of childbearing age, contraceptives measures should be used.
Due to the genotoxic effect in animal studies, men taking VIRGAN are advised to use local contraceptive measure (as condom) during treatment and for up to three months thereafter.

Overdose of  Virgan 1.5 mg/g eye gel:

There is practically no risk of adverse events due to accidental oral ingestion since a tube of 5g contains 7.5mg ganciclovir compared to the daily adult i.v. dose of 500-1000mg.
In the unlikely event of overdose, dialysis and hydration may be of benefit in reducing drug plasma levels.
Toxic manifestations seen in animals given very high single intravenous doses of ganciclovir (500mg/kg) included emesis, hypersalivation, anorexia, bloody diarrhoea, inactivity, cytopenia, abnormal liver function tests and BUN, testicular atrophy and death.

Shelf life:

• In the unopened container: 3 years.
• after opening the tube: 4 weeks.

Special precautions for storage:

Do not store above 25°C.
Keep out of the reach of children.